Jianjun Hu

Jianjun Hu brings more than 16 years of experience in bioanalytical services supporting drug development for large molecules, with expertise in assay development, optimization and validation for PK, immunogenicity and PD assays on numerous platforms under GLP regulations for support of preclinical and clinical studies.

Jianjun earned his Bachelor of Science in biopharmaceutical engineering from Hubei University of Technology and his Master of Biochemical Engineering from Shanghai University.

Lee Goodwin, PhD

Dr. Lee Goodwin serves as global lead for Labcorp’s liquid chromatography-mass spectrometry (LC-MS) Bioanalytical Services (Indianapolis, Madison, Harrogate and Huntingdon), managing the operations and support teams conducting bioanalytical studies for Labcorp clients. Lee has more than 20 years of experience in the pharmaceutical industry across preclinical and clinical drug development with expertise in Bioanalysis, DMPK and Central Laboratory Services.

Graeme Evans

Graeme Evans joined Labcorp Bioanalytical Services in 1994 and has more than 25 years of experience in bioanalytical services and analytical research including bioanalytical chemistry, immunochemistry and ligand-binding assay platforms. Currently, Graeme leads Global Immunochemistry for Bioanalytical Services focusing on method development and validation.

Graeme has published articles in Bioanalysis Journal as well as works on LC-MS/MS strategies for therapeutic antibodies. He graduated from Prince Henry’s Grammar School in Otley, U.K.

Jennifer Courtney, PhD

Dr. Jennifer Courtney started her career as a consultant in Washington, D.C., performing analyses of chronic, subchronic, oncogenic and neurotoxic studies of several pesticides and toxic chemicals. She served as principal reviewer for 12 neurotoxic studies and contributed to the completion of approximately 30 Data Evaluation Reports for the EPA’s Office of Pesticide Programs.

Two Genetic Causes of Atherosclerosis: Familial Hypercholesterolemia & Elevated Lipoprotein (a)

Moderated by:

Sonal Chandra, MD
Medical Director
MedSci Therapeutic Expertise: Cardiovascular, Metabolic, Neuroscience
Labcorp Drug Development, Inc.

Luke Bi, PhD

Dr. Luke Bi joined Labcorp Bioanalytical Services in 2009 and has more than 30 years of pharmaceutical and lab management experience. Additionally, Luke previously served as a clinical pharmacology reviewer at the FDA and CDER and has extensive experience as a research scientist for prominent pharmaceutical companies.

Luke is currently head of Bioanalytical Services in China and is the author of over 20 peer-reviewed journal articles and industry presentations.

Aradhana Ghosh, MD

Dr. Aradhana Ghosh is a board-certified medical oncologist with expertise in clinical informatics and a career that has spanned both patient care and digital health. She obtained her medical degree from Albany Medical College, completed her internal medicine residency at Temple University, followed by subspecialty fellowship training in  hematology-oncology at New York Hospital - Cornell. After completing her medical training, Dr.

Labcorp's planned spin-off, Fortrea, to host 2023 Investor Day

BURLINGTON, N.C. , June 5, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced Fortrea, the new company to be formed by the planned spin-off of Labcorp's Clinical Development and Commercialization Services business, will host its inaugural Investor Day

AMP: Association for Molecular Pathology (Europe Congress)